|
1
|
Bloom MW, Hamo CE, Cardinale D, Ky B,
Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR
and Butler J: Cancer Therapy-Related cardiac dysfunction and heart
failure part 1: definitions, pathophysiology, risk factors, and
imaging. Circ Heart Fail. 9:e0026612016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perez IE, Alam ST, Hernandez GA and
Sancassani R: Cancer therapy-related cardiac dysfunction: An
overview for the Clinician. Clin Med Insights Cardiol.
13:11795468198664452019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cardinale D, Colombo A, Bacchiani G,
Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N,
Curigliano G, et al: Early detection of anthracycline
cardiotoxicity and improvement with heart failure therapy.
Circulation. 131:1981–1988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rossi M, Carioli G, Bonifazi M, Zambelli
A, Franchi M, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C
and Negri E: Trastuzumab for HER2+ metastatic breast cancer in
clinical practice: Cardiotoxicity and overall survival. Eur J
Cancer. 52:41–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ashif I, Mohammad KI, Sumit S, Ansari MA,
Najmi AK, Ali SM, Ali J and Haque SE: Molecular mechanism involved
in cyclophosphamide-induced cardiotoxicity: Old drug with a new
vision. Life Sci. 218:112–131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Expert Consensus for Multimodality Imaging
Evaluation of Adult Patients during and after Cancer Therapy, . A
Report from the American Society of Echocardiography and the
European Association of Cardiovascular Imaging. J Am Soc
Echocardiog. 27:911–939. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Avila MS, Ayub-Ferreira SM, de Barros
Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud
VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, et
al: Carvedilol for prevention of chemotherapy-related
cardiotoxicity: The CECCY trial. J Am Coll Cardiol. 71:2281–2290.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang S, Zhao Q, Yang ZG, Diao KY, He Y,
Shi K, Shen MT, Fu H and Guo YK: Protective role of beta-blockers
in chemotherapy-induced cardiotoxicity-a systematic review and
meta-analysis of carvedilol. Heart Fail Rev. 24:325–333. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang K, Zhang Y, Liu W and He C: Effects
of angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker use on cancer therapy-related cardiac dysfunction: A
meta-analysis of randomized controlled trials. Heart Fail Rev.
26:101–109. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: The Task Force for
the Diagnosis and Treatment of Acute and Chronic Heart Failure of
the European Society of Cardiology (ESC). Developed with the
special contribution of the Heart Failure Association (HFA) of the
ESC. Eur Heart J. 37:2129–2200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McMurray JJ, Packer M, Desai AS, Gong J,
Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg
K, et al: Angiotensin-neprilysin inhibition versus enalapril in
heart failure. N Engl J Med. 371:993–1004. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA statement. BMJ. 339:b25352009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
White PD and Myers MM: The classification
of cardiac diagnosis. JAMA. 77:1414–1415. 1921. View Article : Google Scholar
|
|
14
|
Howick J, Chalmers I and Glasziou P: The
oxford 2011 levels of evidence. Oxford, UK: Oxford Centre for
Evidence-Based Medicine; 2011
|
|
15
|
Murad MH, Sultan S, Haffar S and
Bazerbachi F: Methodological quality and synthesis of case series
and case reports. BMJ Evid Med. 23:60–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rashid M, Rajan AK, Chhabra M and Kashyap
A: Levetiracetam and cutaneous adverse reactions: A systematic
review of descriptive studies. Seizure. 75:101–109. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheppard CE and Anwar M: The use of
sacubitril/valsartan in anthracycline-induced cardiomyopathy: A
mini case series. J Oncol Pharm Pract. 25:1231–1234. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gregorietti V, Fernandez TL, Costa D,
Chahla EO and Daniele AJ: Use of Sacubitril/valsartan in patients
with cardio toxicity and heart failure due to chemotherapy.
Cardiooncology. 6:242020.PubMed/NCBI
|
|
19
|
Vecchis RD and Paccone A: A case series
about the favorable effects of sacubitril/valsartan on
anthracycline cardiomyopathy. SAGE Open Med Case Rep.
8:2050313X209521892020.PubMed/NCBI
|
|
20
|
Martín-García A, Díaz-Peláez E,
Martín-García AC, Sánchez-González J, Ibáñez B and Sánchez PL:
Myocardial function and structure improvement with
sacubitril/valsartan in cancer therapy-induced cardiomyopathy. Rev
Esp Cardiol (Engl Ed). 73:360–271. 2020.PubMed/NCBI
|
|
21
|
Martín-Garcia A, López-Fernández T, Mitroi
C, Chaparro-Muñoz M, Moliner P, Martin-Garcia AC, Martinez-Monzonis
A, Castro A, Lopez-Sendon JL and Sanchez PL: Effectiveness of
sacubitril-valsartan in cancer patients with heart failure. ESC
Heart Fail. 7:763–767. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure. Eur J Heart Fail.
18:891–975. 2016.(In Polish). View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamo CE, Bloom MW, Cardinale D, Ky B,
Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR
and Butler J: Cancer Therapy-related cardiac dysfunction and heart
failure part 2: Prevention, treatment, guidelines, and future
directions. Circ Heart Fail. 9:e0028432016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dadson K, Calvillo-Argüelles O,
Thavendiranathan P and Billia F: Anthracycline-induced
cardiomyopathy: Cellular and molecular mechanisms. Clin Sci (Lond).
134:1859–1885. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu QC, Bai BC, Tian C, Li D, Yu H, Song B,
Li B and Chu X: The molecular mechanisms of cardiotoxicity induced
by HER2, VEGF, and tyrosine kinase inhibitors: An updated review.
Cardiovasc Drug Ther. 36:511–524. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu C, Li D, Li Z and Zhai C: Effect of
sacubitril/valsartan on inflammation and oxidative stress in
doxorubicin-induced heart failure model in rabbits. Acta
Pharmaceutica. 71:473–484. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang CY, Chen JY, Kuo CH, Pai PY, Ho TJ,
Chen TS, Tsai FJ, Padma VV, Kuo WW and Huang CY: Mitochondrial
ROS-induced ERK1/2 activation and HSF2-mediated AT1 R upregulation
are required for doxorubicin-induced cardiotoxicity. J Cell
Physiol. 233:463–475. 2018. View Article : Google Scholar : PubMed/NCBI
|
